On October 5, 2021 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will present clinical and translational data from the Phase 2 SPEARHEAD-1 trial at the Connective Tissue Oncology Society (CTOS) meeting(Press release, Adaptimmune, OCT 5, 2021, View Source [SID1234590810]). The Company will also present translational data based on the patients for whom safety and efficacy were recently reported at ESMO (Free ESMO Whitepaper) from the Phase 1 SURPASS trial, as well as a data update from the four patients treated in the Radiation sub-study of the Phase 1 trial with afami-cel, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) meeting. Abstracts are available online on the meetings’ web sites.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At CTOS, we will present clinical and translational data updates from our SPEARHEAD-1 trial. Data from this trial will form the basis of our first BLA submission next year for afami-cel in synovial sarcoma and MRCLS," said Elliot Norry, Adaptimmune’s Chief Medical Officer. "During SITC (Free SITC Whitepaper), we will present translational data from the SURPASS trial with our next-gen therapy ADP-A2M4CD8, as well as clinical data from a sub-study combining low-dose radiation with afami-cel. These two trials represent investigational approaches to improving the potency of our SPEAR T-cells. Understanding how we can continually enhance our T-cell therapies, so as to ultimately improve clinical outcomes for patients, is a key focus of our translational and early phase clinical research."

CTOS Meeting

Abstract Title: SPEARHEAD-1: A Phase 2 trial of afamitresgene autoleucel (formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (Abstract #1080870)
Oral presentation: November 12, 2021, in the Immunotherapy & Immune Microenvironment Session starting at 10:00 a.m. EST. Presenter: Dr. Brian Van Tine, Associate Professor of Medicine at Washington University School of Medicine in St. Louis

Abstract Title: SPEARHEAD-1 preliminary translational insights from a Phase 2 trial of afamitresgene autoleucel (formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (Abstract #1080366)

Poster Presentation: November 12, 2021, 2:30 p.m. – 3:15 p.m. EST during the Immunology & Immunotherapy Session. Presenter: Dr. Sandra D’Angelo, Medical Oncologist at Memorial Sloan Kettering Cancer Center
At CTOS, Adaptimmune will host its first virtual medical symposium on Thursday, November 11, 4:30-6:30 p.m. EST.

SITC meeting

Abstract Title: Enhancement of TCR-engineered T-cells targeting MAGE-A4 antigen by co-expression of CD8α and inhibition of AKT signaling during ex vivo T-cell expansion (Abstract #373)
Poster presentation: November 12-14, 2021, 7:00 a.m – 5:00 p.m. EST. Presenter: Alex Tipping, Adaptimmune
Abstract Title: Radiation sub-study to characterize safety and tolerability of low-dose radiation in combinations with afami-cel in patients with advanced cancers (Abstract #376)

Poster Presentation: November 12-14, 2021, 7:00 a.m. – 5:00 p.m. EST. Presenter: Dr. James W. Welsh, Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center

On October 5, 2021 AbbVie (NYSE: ABBV) reported that it will announce its third-quarter 2021 financial results on Friday, October 29, 2021, before the market opens (Press release, AbbVie, OCT 5, 2021, View Source [SID1234590808]). AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 5, 2021 Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, reported it will be presenting at the LD Micro Main Event, which is being held in-person and virtually from October 12th through 14th, 2021 (Press release, Scopus BioPharma, OCT 5, 2021, View Source [SID1234590807]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology, which Scopus announced in September 2021.

Alan Horsager, Ph.D., President — Immuno-Oncology of Scopus and President and Chief Executive Officer of Duet, will be presenting in-person on behalf of the company. Dr. Horsager’s presentation will be part of Track 4 on Tuesday, October 12, 2021 at 11:00 AM Eastern Time / 8:00 AM Pacific Time at the Luxe Sunset Bel-Air in Los Angeles. The presentation will also be available for viewing on-demand on the LD Micro conference website. Management will be available for one-on-one meetings to be held throughout the conference.

Investors interested in attending the conference in-person or virtually can register here. Once registered, you can request one-on-one meetings with the company through the conference website.

Dr. Horsager recently presented at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society during which he discussed data from two different studies that suggest that DUET-01 and DUET-02, two of Duet’s unique bifunctional oligonucleotides, can expand the reach and efficacy of cancer immunotherapies beyond certain standard-of-care treatments.

As previously announced, Scopus will also be presenting at The MicroCap Rodeo’s Fall Harvest Best Ideas Conference on Wednesday, October 6, 2021 at 5:00 PM Eastern Time. Investors interested in attending the virtual conference can register here.

About LD Micro Main Event

The 2021 LD Micro Main Event (XIV) will be held at the Luxe Sunset Bel-Air in Los Angeles from October 12th through 14th, 2021. The festivities run from 8:00 AM Pacific Time through 5:30 PM Pacific Time on October 12th and 13th with a morning session on October 14th. This three-day, investor conference is expected to feature around 150 companies, presenting for 25 minutes each, as well as several influential keynotes in-person. For more information, please contact [email protected].

About the Duet Platform

Duet Therapeutics integrates the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform. Olimmune was acquired by Scopus in June 2021. Duet is a wholly-owned subsidiary of Scopus.

The Duet Platform is comprised of three distinctive, complementary CpG-STAT3 inhibitors:

– RNA silencing CpG-STAT3siRNA ("DUET-01")
– Antisense CpG-STAT3ASO ("DUET-02")
– DNA-binding inhibitor CpG-STAT3decoy ("DUET-03")
DUET-01 is in a Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma. Duet expects to file two INDs for DUET-02 in Q4 2022 in genitourinary and head & neck cancers, with clinical Phase 1 trials beginning in Q1 2023 in the United States. Duet is also evaluating combination therapies with checkpoint inhibitors.

On October 5, 2021 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, reported that it will host a Virtual R&D Day on 11 October 2021 at 1:00pm BST (8:00am EDT) (Press release, Redx Pharma, OCT 5, 2021, View Source [SID1234590806]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The R&D Day will include an update from the Company’s leadership team on Redx’s RXC004 programme and the potential of porcupine inhibition in Wnt-ligand driven colorectal, pancreatic and biliary cancers. There will also be an update on the Phase 1 study of RXC007, the Company’s selective ROCK2 inhibitor, being developed for idiopathic pulmonary fibrosis.

The programme includes presentations from leading experts:
· Professor Scott Kopetz, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Presentation Title: ‘Potential of Porcupine Inhibition with RXC004 in Genetically Selected Patients with Metastatic MSS Colorectal Cancer’
· Professor Toby Maher, Professor of Medicine and Director of Interstitial Lung Disease, Keck School of Medicine, University of Southern California, Los Angeles Presentation Title: ‘Idiopathic Pulmonary Fibrosis’
· Professor Gisli Jenkins, Faculty of Medicine, National Heart & Lung Institute, Imperial College London
Presentation Title: ‘The Importance of ROCK in Fibrosis’
To register for the webcast, please email [email protected]. A recording of the webcast will be available on Redx’s website after the event

On October 5, 2021 Orum Therapeutics, a preclinical biotech pioneering the development of tumor-directed targeted protein degraders to improve cancer treatment, reported the appointment of Olaf Christensen, M.D., as Chief Medical Officer (Press release, Orum Therapeutics, OCT 5, 2021, View Source [SID1234590805]). He will lead the clinical development of Orum’s first-in-class targeted protein degraders from the company’s Antibody neoDegrader Conjugate (AnDC) platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We welcome Olaf to the team at this important time for Orum as we transition into a clinical stage biotech," said Sung Joo Lee, Ph.D., Founder and CEO, Orum Therapeutics. "Olaf brings extensive experience in oncology drug development, and we look forward to his leadership in realizing our vision of translating innovative science into breakthrough medicines."

"I am excited to join the Orum Therapeutics team, which works at the cutting edge of targeted protein degradation therapy," said Dr. Christensen. "Orum’s AnDC platform has the potential to steer the power of protein degraders with the precision of ADC technology in multiple indications with high unmet clinical need for the benefit of cancer patients. We are at the beginning of an exciting journey to bring this new class of drugs to patients."

Dr. Christensen has more than 15 years of experience in oncology drug development as an executive leader overseeing phase 1 through phase 4 clinical projects. Most recently, he was Vice President, Head of Oncology Global Clinical Development at EMD Serono, the healthcare business of Merck KGaA in the U.S. and Canada, where he was responsible for development of early to late stage pipeline compounds including immuno-oncology and targeted therapies. Earlier in his career, he worked at Bayer Pharmaceuticals and subsequently in the immuno-oncology clinical development group at Bristol Myers Squibb. He received his M.D. degree at the Albertus Magnus University Cologne, Germany, completed a dissertation in immunotherapy, and trained in oncology at the Clinic for Hematology/Oncology at the University of Heidelberg, Germany.